FDA approves cord-blood therapy
The US Food and Drug Administration has approved an umbilical cord blood-based therapy for blood-cancer patients requiring a stem cell transplant. Gamida Cell’s Omisirge (omidubicel) is an allogeneic source of hematopoietic stem cells for transplant, particularly in cases where patients have no matched adult bone marrow donors nor peripheral blood-derived stem cells. Gamida Cell uses nicotinamide — vitamin B3 — to expand umbilical cord blood cells in vitro. Nicotinamide upregulates transcription factors important for stem cell renewal and DNA repair and downregulates those that activate cell differentiation. The lab-expanded allogeneic cells have better marrow homing and engraftment potential, resulting in faster hematopoietic recovery, lower risk of infection and overall better clinical outcomes than with current treatments.
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 per month
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
FDA approves cord-blood therapy.
Nat Biotechnol 41, 589 (2023). https://doi.org/10.1038/s41587-023-01808-6
Download citation
-
Published:
-
Issue Date:
No comments: